We recently reported that degenerating motor neurons of superoxide dismutase mutant 1 (SOD1 G93A ) rodents exhibit immunoreactivity to P2X 4 antibodies. Neurons with strong P2X 4 -like immunoreactivity (P2X 4 -LIR) do not show an apoptotic phenotype and are often associated with microglial cells that display neuronophagic activity. Western blot analysis showed that P2X 4 antibodies recognize not only the P2X 4 adenosine triphosphate receptor protein but also a hitherto unidentified lowYmolecular weight band. Here, we identify the molecular counterpart of the strong P2X 4 -LIR observed in association with neuronal degeneration in SOD1 G93A animals. After matrix-assisted laser desorption/ionization time-of-flight, we found that the lowYmolecular weight P2X 4 -immunoreactive protein was SOD1. Further analysis demonstrated that the P2X 4 antibody recognizes a form of misfolded mutant SOD1
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease that affects the upper and lower motoneurons (MNs) in the cerebral cortex, brainstem, and spinal cord. It results in progressive MN loss, muscle paralysis, and atrophy, leading to death within a few years. Most ALS cases occur sporadically, but approximately 10% are inherited or familial (FALS) . In approximately 20% of patients with FALS, the disease is caused by mutations in the gene encoding Cu/Zn-superoxide dismutase (SOD1) (1) . Transgenic animals that overexpress mutant SOD1 develop a disease with clinical and pathological similarities to human FALS (2, 3), but ALS does not develop in SOD1-deficient mice (4) .
Although the precise mechanism by which SOD1 mutations cause MN death is still unknown, there is now a general consensus that the mutations lead to an increase in toxic function, which in turn leads to MN loss because of a mechanism involving non-neuronal cells. For example, degeneration of mutant SOD1-expressing MNs is delayed when they associate with WT non-neural cells (5, 6) . Chronic microglial neuroinflammation with increased production of neurotoxic substances is well documented in ALS (7) . In transgenic animals, expression of mutant SOD1 by microglia results in their activation and the release of factors that kill MNs (8) , whereas the reduction of mutant SOD1 in microglial cells is neuroprotective (9) . From these studies, it has been deduced that disease initiation depends on expression of mutant SOD1 within MNs and that disease progression depends on the inflammatory response produced by mutantexpressing microglial cells; however, this interpretation is controversial (10) . A more direct relationship between mutant SOD1 and neuroinflammation was deduced from studies demonstrating that although both normal SOD1 and mutant SOD1 are cytosolic proteins, they may also be secreted to the extracellular space (11, 12) ; the secreted extracellular mutant SOD1 may then induce microglial activation and MN death (12) , pointing to a prominent pathogenetic role for secreted mutant SOD1 in FALS.
Other recent studies indicate that astrocytes may contribute to the killing of MNs in ALS (13Y16). Confining the expression of mutant SOD1 in microglia, astrocytes, or neurons was not sufficient to induce MN disease in mice, however (8, 17Y19) . It also seems that the expression of mutant SOD1 in oligodendrocytes does not contribute to the initiation of MN degeneration (6) . The way in which MNs die in ALS is the subject of some debate because there are apparently contradictory observations from biochemical and morphological analyses as follows: neither apoptotic morphology nor apoptotic markers are found in morphological studies of degenerating MNs in ALS and SOD1 mutant mice (20Y23); biochemical activation of apoptotic signaling pathways has been reported in ALS spinal cord; and the beneficial effects of its inhibition in model systems have also been observed (21) . Recently, we described how degenerating neurons in SOD1
G93A rats and mice were labeled using antibodies against the P2X 4 subunit of the adenosine triphosphate (ATP) receptor (23) . Dying neurons displaying strong P2X 4 -like immunoreactivity (PX 4 -LIR) did not exhibit apoptotic morphology, nor did they display positive labeling to apoptotic markers such as active caspase or terminal deoxynucleotidyl transferase dUTP nick end labeling reaction. We observed, however, that massive microglial recruitment with neuronophagic activity occurred around neurons with positive P2X 4 -LIR. This seems to be relevant because the time course for acquiring neuronal P2X 4 -LIR correlates well with disease progression in the SOD1 G93A animal ALS models. The use of this antibody allows reliable detection of degenerating neurons in cerebral cortex in transgenic SOD1 animals and permitted demonstration of the presence of degenerating cerebellar Purkinje cells and aminergic brainstem neurons in these animals (23) . The obvious question deriving from this study is whether strong upregulation of the P2X 4 subunit of the ATP receptor underlies these changes. This was not conclusively demonstrated by our previous report. Indeed, we found that in Western blots of spinal cord extracts of SOD1 G93A rats, the P2X 4 antibody detected an unidentified protein band that migrated at a lower molecular weight (MW) than expected for P2X 4 . Here, we specifically addressed this issue with the aid of proteomics and found that P2X 4 antibodies cross-react with misfolded forms of mutant SOD1 that are present in neurons but not in glial cells. We suggest that neuronal SOD1
G93A conformers with P2X 4 -LIR may have pathogenetic relevance in the promotion of neuroinflammation because they were able to activate WT microglia and astroglia when injected intracerebrally into normal animals.
MATERIALS AND METHODS

Animals
Sprague-Dawley NTac:SD-TgN (SOD1 G93A ) L26H rats were obtained from Taconic Farms (Germantown, NY). Upon arrival, the animals were kept in a strictly controlled environment. Wild-type (WT) Sprague-Dawley rats were also purchased from Taconic Farms. Adult male C57BL/6J mice were purchased from Charles River Laboratory (Wilmington, MA) at 2 months of age. Samples from mice that overexpressed SOD1
G93A (B6SJL-TgN[SOD1-G93A]1Gur) or SOD1 WT (B6SJL-TgN[SOD1]2Gur) from Jackson Laboratory (Bar Harbor, ME) were also used. Appropriate rules and procedures were followed (Generalitat de Catalunya DOGC 2073, 1995) and approved by the ethical committee for animal testing of the Universitat de Lleida.
Histology and Immunohistochemistry
Animals (n = 8) were deeply anesthetized with pentobarbital and transcardially perfused with physiological saline solution followed by 4% paraformaldehyde in 0.1 mol/L PB at pH 7.4. Samples of spinal cord were postfixed overnight in the same solution, cryoprotected in 30% sucrose, and frozen for cryostat sectioning. Transverse sections, 16-Km thick, were washed in PBS containing 0.1% Triton X-100 for 15 minutes, blocked in 3% normal goat serum for 30 minutes, and incubated overnight at 4-C with the primary antibody. The primary antibodies used were polyclonal rabbit anti-P2X 4 (1:500; Alomone Labs, Jerusalem, Israel); monoclonal mouse anti<neuronal nuclei ([anti-NeuN] 1:500; Chemicon International, Temecula, CA); polyclonal rabbit antiYglial fibrillary acidic protein ([anti-GFAP] 1:400) from Chemicon or, alternatively, when required for double immunofluorescent labeling with anti-ionized calcium binding adaptor molecule 1 (Iba-1), polyclonal chicken anti-GFAP (1:1000; Abcam, Cambridge, UK); polyclonal sheep antiYsuperoxide dismutase (Cu/Zn) ([anti-SOD1] 1:1000; Calbiochem, Darmstadt, Germany); polyclonal rabbit antiYIba-1(1:500; Wako Chemical, Neuss, Germany). For immunofluorescence, washed sections were directly incubated for 1 hour with an appropriate secondary antibody (Alexa Fluor 488, Alexa Fluor 546 from Molecular Probes (Eugene OR) or Cy3 from Jackson ImmunoResearch Laboratories (West Grove, PA). Fluorochrome 4 ¶,6-diamidino-2-phenylindole dihydrochloride (DAPI) was usually applied at 50 ng/mL. To identify microglial cells, some spinal cord sections were incubated with fluorescein isothiocyanateYconjugated Bandeiraea simplicifolia lectin (BS-1, 30 Kg/mL; Sigma-Aldrich, Alcobendas, Spain) or the monoclonal mouse anti-CD11b (OX42, 1:100; Serotec, Oxford, UK). Images were obtained using an Olympus BX51 (Hamburg, Germany) epifluorescence microscope equipped with a cooled CCD camera (DP30BW). A FluoView 500 Olympus confocal laser-scanning microscope was also used. Colocalization analysis was performed under Olympus FV500 software.
For studies of mouse microglial cells after intracerebral SOD1 injections, Iba-1 immunostaining was performed in brain serial coronal sections (80-Km thick) obtained with a vibratome. Sections were collected in 0.1 mol/L PB, permeabilized in PBS with 0.1% Triton X-100, blocked in 10% normal goat serum for 30 min, and incubated overnight with the antiYIba-1 antibody at 4-C. Sections were then incubated with a biotinylated goat anti-rabbit antibody (1:100; Vector, Burlingame, CA) and processed for immunoperoxidase staining according to standard ABC procedures (Vectastain; Vector).
For electron microscopic examination, animals were perfused with a mixture of 1% glutaraldehyde and 1% paraformaldehyde in 0.1 mol/L PB. Dissected tissues were postfixed in 1% osmium tetroxide and processed for Embed 812 embedding according to standard procedures. Ultrathin sections were counterstained with uranyl acetate and lead citrate. were examined. Ultrastructural immunolabeling with anti-P2X 4 was performed as previously described (23) .
Preparation of Spinal Cord Fractions
Animals (n = 10 WT; n = 14 SOD1 G93A ) were killed using lethal doses of pentobarbital. Spinal cords were rapidly dissected, frozen in liquid N 2 , and stored at j80-C until use. Samples were homogenized in 10 volumes of ice-cold buffer (0.32 mol/L sucrose, 10 mmol/L HEPES pH 7.4, 2 mmol/L EDTA, containing the protease inhibitor cocktail (Sigma P8340) and homogenized using 10 to 15 strokes of a motordriven glass-Teflon homogenizer. Samples were spun at 1,000 Â g for 15 minutes to remove pelleted nuclear fraction (P1). Supernatants (S1) were taken and spun at approximately 200,000 Â g (50,000 rpm for 30 minutes in a Beckman 70.1 Ti rotor) to yield crude cytosol (S2) and crude membrane pellets (P2). Pellets were resuspended in homogenization buffer and spun again at approximately 200,000 Â g to yield washed crude membrane pellets (P2 ¶). Pellets were resuspended in HEPES-lysis buffer (50 mmol/L HEPES pH 7.4, 2 mmol/L EDTA, with protease inhibitor cocktail). Protein concentrations were measured by the Bradford method, and samples were stored at j80-C.
Electrophoresis and Western Blotting
Samples were separated according to size through denaturing 11% sodium dodecyl sulfateYpolyacrylamide gel electrophoresis (SDS-PAGE). An equal amount of protein from each sample was heated at 100-C for 5 minutes with an equivalent volume of sample buffer (containing 8% SDS and 2% mercaptoethanol) and loaded onto polyacrylamide gels. The proteins were electrotransferred to a nitrocellulose membrane in Tris-glycine-methanol buffer. The membrane was blocked for 1 hour at room temperature (RT) in a blocking solution mixture of 5% nonfat dry milk, 0.1% Tween 20, and TBS. The membrane was then incubated for 2 hours at RT with primary antibody. The membrane was rinsed once with TBS-Tween 20 for 15 minutes, washed twice with blocking solution for 5 minutes, and then incubated for 1 hour at RT in peroxidase-labeled secondary antibodies from Amersham (Buckinghamshire, UK). The blot was washed once for 15 minutes, once for 10 minutes, and 3 times for 5 minutes, and then processed for analysis using a Supersignal chemiluminescent detection kit (Pierce, Rockford, IL), as described by the manufacturer.
Two-Dimensional Electrophoresis
A protocol similar to that described by Carrette et al (24) was followed. The volume carrying 100 Kg of total soluble protein was mixed with the rehydration buffer containing 8 mol/L urea, 0.5% (vol/vol) CHAPS, 50 mmol/L dithiothreitol (DTT), 0.5% (vol/vol) Biolytes (Bio-Rad, Hercules, CA) to bring it to a final volume of 200 KL. A trace amount of bromophenol blue was added to the sample, which was then placed in an 11-cm strip holder. The IPG strip (pH 3Y10, 11 cm; Bio-Rad) was placed over the protein sample and overlaid with a cover fluid (mineral oil). The IPG strip was then allowed to actively rehydrate with the protein sample for 2 hours, which was directly linked to a 6-step focusing protocol (6 hours 30 V, 3 hours 60 V, 1 hour 200 V, 1 hour 500 V, 1 hour 5,000 V, 1 hour 8,000 V). The whole procedure was conducted at a fixed temperature of 20-C. The strip gel was incubated in equilibration buffer
containing 130 mmol/L DTT for 10 minutes with gentle agitation, followed by incubation in equilibration buffer supplemented with 135 mmol/L iodoacetamide for 10 minutes at RT. The IPG strip was then placed on the 10% SDS-PAGE gel. The protein standards were loaded adjacent to the pH 3.0 end. Electrophoresis was carried out at 50 mA. The Western blotting was as previously described. To visualize protein spots, the PAG was subsequently stained with Flamingo Fluorescent Gel Stain (Bio-Rad) or silver nitrate (Silver Staining Kit; GE Healthcare, Uppsala, Sweden).
Identification of Proteins by MALDI-TOF Mass Spectrometry
We followed a previously described procedure (25) . The bands were manually sliced from the gel and individually digested overnight with 100 to 150 ng of trypsin (Promega, Alcobendas, Spain) at 37-C using a Montage In-Gel DigestZP (Millipore, Billerica, MA) according to the manufacturer's standard protocol. The resulting peptides were dried and resuspended in 0.1% trifluoroacetyl acid. Then, 0.5 KL of them were mixed with the same amount of >-cyano-4-hydroxycinnamic acid (3 mg/mL). Next, they were analyzed using a matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) Voyager DE Pro mass spectrometer (Applied Biosystems, Foster City, CA) operated in delayed extraction reflector mode, an accelerating voltage of 20 kV and with a 90-nanosecond pulse delay time, 75% grid voltage, and a guide wire voltage of 0.005%. Spectra were accumulated for 100 laser shots and were visualized and analyzed using Data Explorer software version 4.2 (Applied Biosystems). Monoisotopic peaks were identified using the Protein Prospector MS-Fit software version 3.2 and using Swiss-Prot for the database search.
Immunoprecipitation
Rat spinal cord samples were homogenized in nondenaturing lysis buffer (20 mmol/L Tris HCl pH 8, 137 mmol/L NaCl, 10% glycerol, 1% Nonidet P-40, 2 mmol/L EDTA) using a glass homogenizer. Volumes of lysis buffer had to be determined in relation to the amount of tissue present. Samples were centrifuged in a microcentrifuge for 10 minutes at 12,000 rpm and at 4-C and then placed on ice. The supernatant was aspirated and placed in a fresh tube, then kept on ice and incubated with the antibody (1:200 polyclonal sheep anti-SOD1 from Calbiochem or 1:250 polyclonal rabbit anti-P2X 4 from Alomone Labs) overnight at 4-C under agitation. Meanwhile, the protein A Sepharose beads (Amersham Pharmacia Biotech AB) were prepared. Then, 100 mg of beads were incubated in 1 mL PBS 0.1 mol/L, blocked for 1 hour with 1 mL PBSYbovine serum albumin (1% wt/vol), washed for 1 hour in PBS, and then stored at 4-C .The lysatebeads mixture was incubated at 4-C under rotary agitation for 4 hours. After that, the samples were centrifuged, the supernatant was collected, and the beads were washed in lysis buffer 3 times. Finally, the last supernatant was removed, 25 KL of 2Â loading buffer was added to the beads, and both the first collected supernatant and the samples were boiled at 95-C to 100-C for 5 minutes for ulterior SDS-PAGE and Western blot.
Affinity Chromatography
A Microlink Protein Coupling Kit was used as described by the manufacturer (Pierce Thermo Fisher Scientific, ref no. 20475). The antibody used for coupling was anti-P2X 4 (1 mg/mL; Alomone Labs). Crude cytosol (S2) rat spinal cord proteins were added to the column and incubated for 2 hours at RT. To reduce nonspecific interactions, the column was washed with 0.5 mol/L NaClY0.02% Tween-20. Then, 300 KL of coupling buffer was added to remove the unbound fraction. The column was eluted by incubation with 100 KL ImmunoPure elution buffer for 10 minutes at RT. The recovered protein was neutralized by adding 5 KL Tris 1 mol/L, pH = 9. The eluted and unbound fractions were used in stereotaxic experiments. After analysis by Western blotting and Coomassie staining, only one approximately 22-kd band was detected on eluted fraction.
SOD1 In Vitro Misfolding
A procedure similar to that described by Rakhit et al (26) was followed. The SOD1 from human erythrocytes was purchased from Sigma. Stock 106 Kmol/L SOD1 in 50 mmol/L HEPES, pH 7.5, was diluted overnight and at RT in 8 mol/L urea, 2 mmol/L DTT, and 1 mmol/L EDTA to a final concentration of 2 Kmol/L. This is referred to as unfolded SOD1. Stock SOD1 was similarly diluted in PBS overnight (folded SOD1). Unfolded SOD1 and folded SOD1 were diluted 1:20 in PBS containing 1 Kg/mL anti-P2X 4 antibody from Alomone Labs and using 2 mg/mL bovine serum albumin from Sigma as a stabilizer. This reaction was incubated for 1 hour at RT. This was followed by immunoprecipitation with 50 KL of washed Protein A Sepharose beads (Amersham) for 1 hour at RT. Supernatants from each reaction were treated as a loading control. Samples were Western blotted using as a primary antibody sheep anti-SOD1.
Intracerebral Injection
Two-month-old adult male C57BL/6J laboratory mice (n = 14) were anesthetized with isoflurane (3% vol) for 1 to 2 minutes and then injected with 2% Rompun (Bayer, Kiel, Germany) and 10% ketamine hydrochloride (Merial, Barcelona, Spain) in 0.9% NaCl (10 KL/g) and placed on a stereotaxic apparatus (ASI Instruments, Warren, MI). The animals received an injection of 1 KL of either erythrocyte human SOD1 WT or SOD1
G93A species immunoisolated by anti-P2X 4 antibody (both at 1 Kg/KL) that was delivered into the hippocampus (j1.0 mm lateral and j1.82 mm dorsoventral from the bregma) at a speed of 1 KL/minute. The delivery needle was left in place for 1 minute and then slowly retracted (1 mm/minute). The incisions were sutured, and the mice were left to recover. The animals were intracardially perfused at 24 hours or 120 hours after the injection. Coronal serial sections of the whole brains were obtained with a vibratome and processed for Iba-1 immunohistochemistry (n = 6 for WT SOD and n = 6 for mutant SOD1; n = 3 after 24 hours and n = 3 after 120 hours, in both conditions). All tissue sections were digitally imaged at low magnification (1.6Â objective); Iba-1 immunoreactivity was quantified by densitometry in the injected (ipsilateral) and in the noninjected (contralateral) hemispheres with a Visilog 6.3 image analyzer (Noesis, Orsay, France). An additional pair of WT and mutant brains were serially sectioned and processed for triple fluorescent staining for simultaneous demonstration of astroglia, microglia, and nuclear morphology using the reagents previously described. Glial fibrillary acidic protein immunoreactivity was evaluated on confocal microscope images obtained after z axis projection of 2-Km-thick opti- 
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G93A -EGFP, and SOD1 A4V -EGFP that were kindly provided by Dr Bradley Turner (Melbourne, Australia) were used for transfection. Cells were fixed at 24 to 48 hours with 4% paraformaldehyde and permeabilized with PBSY0.1% Triton X-100, blocked in normal goat serum and incubated overnight at 4-C in rabbit anti-P2X 4 antibody (Alomone Labs). Immunoreactivity was visualized after incubation with Cy5-conjugated anti-rabbit secondary antibody from Jackson Labs (1:500 in PBS) under an Olympus FV500 confocal microscope. Initially, Cy3-or Alexa Fluor 546Yconjugated secondary antibodies were used, but during sample excitation with 546 helium-neon laser, a shift in the spectral properties of mutant SOD1-EGFP resulting in a high cross-talk between Alexa Fluor 546 and mutant SOD1-EGFP was observed. To circumvent this inconvenience, we used red fluorochrome Cy5 instead.
For calcium imaging, transfected cells grown on glass coverslips were incubated with 5 Kmol/L Fura 2 AM (Invitrogen) dissolved in an extracellular physiological solution containing (in mmol/L) 150 NaCl; 1 CaCl 2 ; 1 MgCl 2 ; 5 KCl; 20 HEPES, pH 7.4; 10 glucose; and 0.1% bovine serum albumin for 30 minutes at 37-C. The coverslips were then inserted into a PH1 (Warner Instrument Corp, Hamden, CT) perfusion chamber that was placed in a Nikon Eclipse TE200 inverted fluorescence microscope equipped with a monochromator and an Orca ER camera (Hamamatsu Photonics, Hamamatsu City, Japan). All of these were done under the control of Aquacosmos software (Hamamatsu Photonics) for calcium imaging. Cells were continuously perfused with the previously mentioned solution. Stimulating agents were added to the perfusion chamber when needed. Ratio images were captured using a 40Â 1.3 NA Nikon S Fluor oil-immersion objective and subsequently analyzed.
RESULTS
P2X 4 Immunolabeling of Degenerating Neurons in SOD1 G93A Animals
Some of the results obtained from our previous work were replicated here. First, conventional fluorescence or confocal microscopy was performed on multilabeled spinal cord sections from SOD1 G93A rats. As shown in Figure 1 , at P30 (the stage at which clinical signs have not yet emerged) many large ventral horn MNs visualized with NeuN immunostaining (Fig. 1A) do not display any substantial P2X 4 immunolabeling (Figs. 1B, C) , nor do they show any structural abnormality when examined in combination with either DAPI or Nissl fluorescent staining (not shown). By contrast, when the disease is fully developed (i.e. P150) and MN loss is conspicuous (Fig. 1D) , the cell bodies and processes of degenerating MNs acquired strong P2X 4 -LIR (Fig. 1E) . Ventral, but not dorsal, root axons showed P2X 4 immunopositivity from P90 on (Figs. 1G, H) . The P2X 4 -LIR was specifically associated with degenerating neurons and was completely dissociated from glial cells. When P2X 4 and GFAP immunostaining were combined, colocalization analysis demonstrated absence of cells with double labeling (Figs. 1PYS) . Similarly, P2X 4 immunolabeling was not found colocalized with either of the microglia cell markers OX-42 (Figs. 1LYO) or BS-1 lectin (Figs. 1TYX) . Nevertheless, P2X 4 -positive neurons were often completely decorated by adjacent microglial cells (Figs. 1IYO) . Degenerating MNs with P2X 4 -positive immunolabeling do not G93A rats at all ages ( Fig. 2A) . The labeling was abolished when the antibody was preincubated with the P2X 4 -immunizing peptide, indicating that it was specific. We hypothesized that the low MW band might have resulted from an abnormal proteolytic cleavage of the P2X 4 receptor protein or could represent another protein unrelated to P2X 4 but shared one or more epitopes with it. To resolve this question, we performed a proteomic analysis using MALDI-TOF mass spectrometry. Proteins were separated by 2-dimensional (2D) electrophoresis, and P2X 4 -immunoreactive spots were identified by comparing silverstained gels with P2X 4 -immunostained 2D Western blots (Fig. 2B) . After spectrum analysis, 7 peptide fragments of SOD1 were recognized (threshold, 7.46 Â 10 4 ). The matched peptides cover 38% of the protein (60 of the 154 amino acids). Thus, the low MW P2X 4 -immunoreactive protein was identified as SOD1 (Fig. 2C) . This result was corroborated by analyzing the pattern of spots obtained after reacting 2D Western blots with either anti-P2X 4 or antiYhuman SOD1 antibodies and assessing their equivalence (Fig. 2D) .
These results suggested that SOD1 G93A and P2X 4 share some epitope(s) that can be recognized by anti-P2X 4 antibodies. By comparing the amino acid sequence of the P2X 4 -immunizing peptide with the complete sequence of human SOD1, we found that the peptide sequence could be aligned within a region of SOD1 comprising between 34 and 53 amino acids of which 3 residues were identical and 8 were similar (Fig. 2E) . This sequence is enriched in hydrophobic amino acids and localizes in the inner region of native monomer in human SOD1, where it is presumably not available for antibody binding in its native form. Indeed, mutated SOD1 in ALS is prone to conformational changes that promote misfolding and the aggregation of toxic forms that accumulate in neuronal and glial cells (27) . To identify native P2X 4 -immunoreactive SOD1
G93A conformers, extracts of soluble and membrane fractions of spinal cord from either SOD1 G93A or WT rats were immunoprecipitated with anti-P2X 4 and anti-SOD1 antibodies. Monomeric SOD1 was immunoprecipitated under nondenaturing conditions with anti-P2X 4 antibodies in either soluble or membrane extracts of presymptomatic (P30) and end-stage (P120) mutant animals (Fig. 3A) . Only traces of SOD1 were immunoprecipitated in WT extracts. High-MW SOD1 aggregates were also immunoprecipitated to some extent at P120. Conversely, the SOD1 monomers that were immunoprecipitated with anti-SOD1 were also immunolabeled with anti-P2X 4 in both soluble and membrane fraction extracts from transgenic animals (Fig. 3B) .
To explore whether the SOD1 epitope cross-reactive with anti-P2X 4 antibodies is better exposed after unfolding, we used a protocol similar to that of Rakhit et al (26) , in which human erythrocyte-derived SOD1 was subjected to immunoprecipitation in its native folded state and after unfolding in the presence of highly concentrated urea. We found that anti-P2X 4 antibody reacted with urea-unfolded SOD1, whereas only trace reaction occurred with native SOD1 (Fig. 3C) . 
SOD1 and P2X 4 Immunostaining in Sections of Spinal Cord Tissue From SOD1 G93A Rats
The relationship between SOD1 and P2X 4 immunostaining was examined in double-fluorescent sections of labeled spinal cords from WT and SOD1 G93A rats. Samples from mice that overexpressed human SOD1 WT were also evaluated. As expected, SOD1 immunostaining was extensive and strong in SOD1 G93A rats in both neuronal and glial cells. The strong P2X 4 -immunoreactive signal in degenerating MNs always colocalized with intense SOD1 immunolabeling. Intense SOD1 immunostaining was, however, also detected in cells and areas devoid of P2X 4 immunolabeling (Figs. 4AYC) . For example, after double labeling with anti-GFAP, SOD1
G93A accumulated in great numbers of astrocytes, whereas P2X 4 immunoreactivity was never associated with astrocytes (Figs. 4JYO) . To evaluate whether acquisition of P2X 4 immunolabeling is a property of SOD1 G93A expressed in degenerating neurons or, alternatively, a mutationindependent characteristic of SOD1, we examined spinal cord sections from mice overexpressing human SOD1 WT; SOD1 immunostaining was not seen in association with P2X 4 -LIR in that case (Figs. 4DYF) . These observations were verified by colocalization analysis (not shown).
Activation of Microglia and Astroglia by Extracellular P2X 4 -Immunoreactive SOD1
G93A Conformers
Mutated SOD1 causes microgliosis and neuron death when it is secreted in the extracellular space (12) . Because many P2X 4 -LIRYpositive degenerating neurons in SOD1 G93A animals are intimately associated with activated microglial cells, we hypothesized that P2X 4 -positive SOD1
G93A conformers would induce microglial activation when applied in vivo. Therefore, we first isolated P2X 4 -positive SOD1 G93A species (SOD1 G93A -P2X 4 -LIR) from extracts of soluble spinal cord from mutant rats by affinity chromatography using a matrix with immobilized anti-P2X 4 antibody. The protein recovered after elution was then dialyzed against PBS and injected into hippocampi of normal WT mice by stereotaxis. Human erythrocyte SOD1 (SOD1 WT) in PBS was injected as a control. Microgliosis was assessed using Iba-1 immunostaining in serial sections of whole brains at 24 hours and 5 days after injection. As shown in Figures 5A to E, microglial activation spread through the brain from the site of the injection and extended to the contralateral hemisphere. The densitometric values of the Iba-1 signal were always higher after administration of SOD1 G93A -P2X 4 -LIR than after administration of SOD1 WT. Microglia activated by SOD1 G93A -P2X 4 -LIR species displayed a hypertrophic and ramified morphology. In another experiment, serial sections of brains injected with either SOD1 WT or SOD1
G93A -P2X4-LIR were double-fluorescent immunolabeled with anti-GFAP and antiYIba-1 for simultaneous visualization of astroglial and microglial cells (Figs. 5FYK) . At 5 days after injection, mutant SOD1 conformers induced extensive astrocytic activation in the injected areas. Activated astrocytes displayed more intense GFAP immunoreactivity, increased cell size and increased numbers of processes compared with astrocytes around the SOD1 WT injection sites. Image analysis studies showed that the relative area occupied by GFAP-positive structures was more than doubled after injection of mutant SOD1 conformers compared with injection of SOD1 WT (Fig. 5K) . 
P2X 4 Cross-Reactive Epitopes of Mutant SOD1 Are Masked in Aggregates
Because misfolded mutant SOD1 is prone to aggregation and neurotoxicity, we investigated the unmasking of the P2X 4 -immunoreactive epitope that occurs during the aggregation of mutant forms of SOD1 in transfected mouse MNlike hybrid cell line NSC-34. These cells were transfected with WT and ALS-linked mutant (G93A and A4V) human SOD1-EGFP. Aggregates of human SOD1 were readily seen in cells expressing G93A or A4V mutations but were more frequent and prominent in the latter. After P2X 4 immunocytochemistry, mutant SOD1 aggregates did not share immunoreactivity to P2X 4 (Fig. 6A) . Because the levels of the band corresponding to the ATP receptor P2X 4 subunit increased in the spinal cord tissue of end-stage G93A rats (23), we assessed the possibility of mutant SOD1 transfection influencing endogenous expression of calcium-permeable ATP receptors. This would be noticeable because treatment with the P2X 4 allosteric modulator of the P2X 4 subtype of ATP receptor increases the survival of SOD1 G93A mice (28) . Changes in intracellular calcium were analyzed in Fura2-loaded NSC-34 cells after stimulation with ATP. Calcium transients were induced by ATP in many control (untransfected) NSC-34 cells but decreased when WT or mutant SOD1 was overexpressed. The decrease was most prominent in cells that overexpress mutant SOD1, indicating that increased function of the P2X 4 receptors is not present in this ALS cellular model (Fig. 6B) .
DISCUSSION
We have demonstrated that the strong P2X 4 -LIR observed during neurodegeneration in SOD1 G93A transgenic animals reveals the accumulation of mutant SOD1 in a particular configuration of misfolding. These accumulations may play a prominent pathogenic role because neurons expressing P2X 4 -LIR recruit neuronophagic microglia and because intracerebral injection of SOD1 G93A -P2X 4 -LIR conformers induced enhanced microglial and astroglial activation compared with control injections in the surrounding brain.
The observed antibody cross-reactivity can be explained by the similarity between the amino acid sequences in the immunizing peptide used in the production of the P2X 4 antibody and in an SOD1 sequence in its inner hydrophobic region. This epitope has a high affinity for the P2X 4 antibody and is unmasked for unknown reasons in degenerating neurons in these transgenic animals. The P2X 4 antibody recognizes unfolded SOD1 in denaturing Western blots; immunoprecipitation is the appropriate procedure for demonstrating the presence of SOD1 G93A -P2X 4 -LIR in tissue homogenates. Misfolded mutant SOD1 is prone to the formation of aggregates that have been considered neurotoxic (29Y33). These aggregates are found in both neurons and glia (34, 35) . We found that aggregates of mutant SOD1 in NSC-34Y transfected cells did not exhibit P2X 4 -LIR. Similarly, we never found P2X 4 -LIR associated with neuronal protein aggregates or within glial cells, indicating that SOD1 G93A -P2X 4 -LIR was unmasked under conditions other than those of protein aggregation. These observations should be considered in relation to the controversies regarding the cytoprotective versus noxious effects of protein aggregates in neurodegenerative diseases and the suggestion that inclusion bodies may protect cells either by sequestering toxic diffuse mutant proteins or by other mechanisms (32, 36, 37) . On the other hand, misfolded soluble SOD1 monomers with externalized hydrophobic regions have been found in tissues from mutant SOD1 mice and may be particularly involved in ALS neurotoxicity (38) . Because misfolded proteins are likely to externalize parts of the hydrophobic interior, it is possible that P2X 4 -LIR epitopes could be unmasked in particularly neurotoxic soluble or oligomeric forms of misfolded mutant SOD1; this would be consistent with cytosolic ultrastructural localization P2X 4 -LIR sites in degenerating neurons (23) .
Although SOD1 is a cytosolic protein and does not contain a translocation signal for entering secretory pathways, it can be secreted to the extracellular space (11) after reaching endoplasmic reticulumYGolgi compartments (12, 39) . Activation of endoplasmic reticulum stress pathways by mutant SOD1 is an early change in most vulnerable MNs in ALS (40) . Unlike SOD1 WT, extracellular mutant SOD1 is able to activate microglial cells that are neurotoxic in primary spinal cord cultures (41) . Here, we have shown that extracellular SOD1
G93A -P2X 4 -LIR conformers induce microglial activation when introduced in normal brain in vivo.
Although it remains to be demonstrated that the crossreacting SOD1 peptide itself causes neuroinflammation, our results suggest that SOD1
G93A -P2X 4 -LIR conformers may induce reactive microgliosis and neuronophagia in ALS. Although controversy remains (10), microgliosis is thought to be a pathogenetic factor in ALS progression (8, 42) and that other immune cells, such as T lymphocytes, may modulate microglial activity (43, 44) . Targeting the microglial response is, therefore, an important potential therapeutic strategy for ALS. In this regard, it has been reported that reducing neurotoxic extracellular SOD1 by means of immunotherapy has a beneficial effect on disease symptoms and improves the life expectancy of mutant SOD1 mice in ALS models (39) . Astrocytic activation is a well-established feature of ALS pathology that occurs both in human and animal models of the disease (45) . Astrocytes bearing SOD1 mutations are neurotoxic for MNs (13Y16), but the induction of astrocytic activation by extracellular mutant SOD1 has not been previously reported. It would be important to investigate whether astrocytes that have been activated by injection of SOD1 G93A -P2X 4 -LIR conformers upregulate their production of molecules that promote neuronal death.
An antibody against SOD1-exposed dimer interface that recognizes SOD1 in misfolded conformation but not in native protein has recently been developed (26) . Degenerating MNs and ventral root axons are labeled in a pattern that is similar to our results with the P2X 4 antibody. Unlike the P2X 4 antibody, however, SOD1-exposed dimer interface also detects inclusion bodies in MNs and astrocytes. This indicates that several distinct forms of misfolded SOD1 must coexist and be differentially distributed in ALS rodents. More recently developed monoclonal antibodies support this assumption and provide valuable new agents for therapeutic strategies (46) .
